{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:59:11Z","timestamp":1790776751725,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca R&D M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104458","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:11:40Z","timestamp":1786547500000},"page":"104458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical assessment of low global warming potential alternatives to HFA-134a in a budesonide, glycopyrrolate, and formoterol fumarate pressurized metered-dose inhaler"],"prefix":"10.1016","volume":"115","author":[{"given":"Kellisa","family":"Lachacz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0355-4082","authenticated-orcid":false,"given":"Ashley","family":"Stoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-5997","authenticated-orcid":false,"given":"Johannes","family":"T\u00f6rnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104458_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1442-200X.2006.02173.x","article-title":"Ability of preschool children to use dry powder inhalers as evaluated by In-Check Meter","volume":"48","author":"Adachi","year":"2006","journal-title":"Pediatr Int"},{"issue":"2","key":"10.1016\/j.xphs.2026.104458_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rehab.2009.11.001","article-title":"The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease","volume":"53","author":"Quinet","year":"2010","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.xphs.2026.104458_bib0003","unstructured":"European Medicines Agency. Questions and answers on data requirements when transitioning to low global warming potential (LGWP) propellants in oral pressurised metered dose inhalers. 2023. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-answers-data-requirements-when-transitioning-low-global-warming-potential-lgwp-propellants-oral-pressurised-metered-dose-inhalers_en.pdf. Accessed April 24, 2026."},{"issue":"4","key":"10.1016\/j.xphs.2026.104458_bib0004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5603\/ARM.a2021.0092","article-title":"Impact of inhalers used in the treatment of respiratory diseases on global warming","volume":"89","author":"Emeryk","year":"2021","journal-title":"Adv Respir Med"},{"key":"10.1016\/j.xphs.2026.104458_bib0005","unstructured":"US Food and Drug Administration. Breztri Aerosphere prescribing information. 2022. Available at: https:\/\/www.breztri.com\/content\/dam\/open-digital\/breztri-consumer\/en\/pdf\/instructions.pdf. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0006","unstructured":"European Medicines Agency. Trixeo Aerosphere summary of product characteristics. 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trixeo-aerosphere-epar-product-information_en.pdf. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106893","article-title":"The environmental burden of inhalation","volume":"204","author":"de Boer","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104458_bib0008","unstructured":"United Nations Environment Programme. The Kigali amendment: the amendment to the Montreal protocol agreed by the twenty-eighth meeting of the parties (Kigali, 10\u201315 October 2016). Available at: https:\/\/ozone.unep.org\/treaties\/montreal-protocol\/amendments\/kigali-amendment-2016-amendment-montreal-protocol-agreed. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0009","unstructured":"United States Environmental Protection Agency. Protecting our climate by reducing use of HFCs. Available at: https:\/\/www.epa.gov\/climate-hfcs-reduction. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0010","unstructured":"European Commission. F-gas legislation. Available at: https:\/\/climate.ec.europa.eu\/eu-action\/fluorinated-greenhouse-gases\/f-gas-legislation_en. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0011","unstructured":"United States Environmental Protection Agency. Substitutes in propellants. Available at: https:\/\/www.epa.gov\/snap\/substitutes-propellants. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0012","first-page":"175","article-title":"Comparative aerosol performance of an HFA-134a based fixed-dose triple combination pMDI to one made with a near-zero carbon footprint propellant","volume":"2023","author":"Lachacz","year":"2023","journal-title":"Respir Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104458_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/17534666261417149","volume":"20","author":"Bednarczyk","year":"2026","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.xphs.2026.104458_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103402","article-title":"Safety of budesonide\/glycopyrronium\/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study","volume":"87","author":"Usmani","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.xphs.2026.104458_bib0015","series-title":"Respiratory Drug Delivery Europe","first-page":"101","article-title":"New cosuspension MDI platform: scientific foundations of mono, dual and triple combination products","author":"Lechuga-Ballesteros","year":"2011"},{"issue":"42","key":"10.1016\/j.xphs.2026.104458_bib0016","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1021\/la302281n","article-title":"Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers","volume":"28","author":"Vehring","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.xphs.2026.104458_bib0017","unstructured":"United States Pharmacopeia. Chapter 601, aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Available at: http:\/\/www.pharmacopeia.cn\/v29240\/usp29nf24s0_c601_viewall.html. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0018","unstructured":"National Council on Radiation Protection and Measurements. Deposition, retention and dosimetry of inhaled radioactive substances: recommendations of the National Council on Radiation Protection and Measurements. 1997."},{"issue":"3","key":"10.1016\/j.xphs.2026.104458_bib0019","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0092-8240(80)80060-7","article-title":"Models of human lung airways and their application to inhaled particle deposition","volume":"42","author":"Yeh","year":"1980","journal-title":"Bull Math Biol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104458_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/jamp.2020.1620","article-title":"On the validation of generational lung deposition computer models using planar scintigraphic images: the case of mimetikos preludium","volume":"34","author":"Olsson","year":"2021","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104458_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105472","article-title":"Pulmonary deposition of budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects","volume":"153","author":"Israel","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104458_bib0022","first-page":"259","article-title":"Therapeutic aerosol: principles and practices","volume":"48","author":"Zainudin","year":"1993","journal-title":"Med J Malaysia"},{"issue":"8","key":"10.1016\/j.xphs.2026.104458_bib0023","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/17425247.2024.2392790","article-title":"The effects of airway disease on the deposition of inhaled drugs","volume":"21","author":"Darquenne","year":"2024","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2026.104458_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4274\/tjps.galenos.2021.77177","article-title":"Quantitative determination of related substances in formoterol fumarate and tiotropium in Tiomate Transcaps\u00ae dry powder inhaler","volume":"19","author":"Gondhale","year":"2022","journal-title":"Turk J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104458_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12249-025-03060-4","article-title":"Materials compatibility considerations for the transition to low global warming potential propellants for pressurized metered dose inhalers","volume":"26","author":"Dohmeier","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.xphs.2026.104458_bib0026","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17425247.2023.2264184","article-title":"Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen","volume":"20","author":"Buttini","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104458_bib0027","unstructured":"European Medicines Agency. Trimbow summary of product characteristics. 2026. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trimbow-epar-product-information_en.pdf. Accessed April 24, 2026."},{"key":"10.1016\/j.xphs.2026.104458_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2026.108814","article-title":"Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate\/formoterol fumarate\/glycopyrronium: The TRECOS study","author":"Singh","year":"2026","journal-title":"Respir Med"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:58Z","timestamp":1790774698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022354926003084"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104458","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical assessment of low global warming potential alternatives to HFA-134a in a budesonide, glycopyrrolate, and formoterol fumarate pressurized metered-dose inhaler","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104458"}}